Prenetics Group (PRE) AI Stock Analysis

• Market Cap: $215.58M
• Dividend Yield: N/A
• Average Volume (3M): 139.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: 123.15%
• EPS Growth: 8.21%
• Country: US
• Employees: 285
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.82
• Shares Outstanding: 11,453,009
• 10 Day Avg. Volume: 121,839
• 30 Day Avg. Volume: 139,535
• PEG Ratio: 0.05
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 2.41
• P/FCF Ratio: -2.46
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: 1.87
• Enterprise Value/Gross Profit: 4.09
• Enterprise Value/Ebitda: -1.47
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: $16.50 ▲(1.60% Upside)

Prenetics Group's stock score is primarily influenced by strong technical momentum, despite significant financial performance and valuation challenges. The company's stable equity base provides some financial stability, but profitability and cash flow improvements are necessary for a higher score.

Prenetics Group Business Overview & Revenue Model

Company Description

Prenetics Group (PRE) is a leading global health and wellness company specializing in genetic testing and digital health solutions. With a focus on providing personalized healthcare insights, Prenetics operates in the biotechnology and healthcare sectors, offering a range of services including DNA testing, health screening, and wellness programs. The company aims to empower individuals with actionable health data to enhance their lifestyle and health outcomes.

How the Company Makes Money

Prenetics generates revenue primarily through its genetic testing services and health solutions. Key revenue streams include direct-to-consumer sales of genetic testing kits, corporate wellness programs, and partnerships with healthcare providers and insurers. Additionally, Prenetics has established significant collaborations with various organizations to offer their testing solutions, which further expands their market reach and drives earnings. The company also leverages technology through its digital platforms, allowing for subscription-based models and one-time service fees, contributing to a diversified revenue base.

Prenetics Group Financial Statement Overview

Summary

Prenetics Group faces significant profitability challenges, with consistent negative net income and cash flow issues. Despite a strong equity base and low leverage, the company needs to improve its cash flow and profitability metrics to enhance financial health.

Income Statement

Prenetics Group has seen fluctuating revenue growth, with recent declines from 2022 to 2023 but a recovery in 2024. Gross profit margin stands at roughly 50%, indicating strong cost management. However, negative EBIT and net income margins highlight ongoing profitability challenges that could impact long-term sustainability.

Balance Sheet

The company maintains a strong equity position with a positive equity ratio, indicative of low leverage and financial stability. The debt-to-equity ratio remains low, though high negative net income affects return on equity. Overall, the balance sheet suggests a relatively stable financial footing but with profitability concerns.

Cash Flow

Operating cash flow remains negative, suggesting challenges in generating cash from operations. Despite this, there is a positive trend in cash flow from investing activities. The free cash flow remains negative, impacting the company's ability to finance operations without external funding. Overall, cash flow management needs improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.52M	30.62M	21.74M	13.16M	275.85M	65.18M
Gross Profit	18.96M	15.40M	8.83M	3.62M	106.13M	26.34M
EBITDA	-52.96M	-51.57M	-47.90M	-214.28M	-157.70M	-1.42M
Net Income	-48.13M	-46.30M	-62.72M	-190.45M	-174.02M	-1.94M
Balance Sheet
Total Assets	204.01M	213.57M	254.17M	307.98M	148.51M	78.88M
Cash, Cash Equivalents and Short-Term Investments	58.53M	62.81M	72.74M	164.20M	45.19M	14.80M
Total Debt	5.15M	5.77M	2.37M	6.65M	5.27M	1.67M
Total Liabilities	42.90M	42.23M	44.01M	67.94M	549.40M	47.88M
Stockholders Equity	160.88M	170.39M	206.36M	237.06M	-400.81M	31.08M
Cash Flow
Free Cash Flow	0.00	-29.94M	-14.68M	8.17M	2.00M	-5.94M
Operating Cash Flow	0.00	-28.87M	-13.76M	14.51M	13.42M	-2.88M
Investing Cash Flow	0.00	38.54M	-82.95M	-46.14M	-22.02M	-5.97M
Financing Cash Flow	0.00	-3.34M	-4.70M	143.32M	29.32M	11.84M

Prenetics Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Positive. The current price of 16.24 is above the 20-day moving average (MA) of 14.53, above the 50-day MA of 11.18, and above the 200-day MA of 7.46, indicating a bullish trend. The MACD of 1.33 indicates Negative momentum. The RSI at 66.63 is Neutral, neither overbought nor oversold. The STOCH value of 77.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRE.

Prenetics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XGN	58 Neutral	$257.88M	―	-87.94%	―	3.89%	7.92%
PRE	55 Neutral	$215.58M	―	-27.01%	―	123.15%	8.21%
ACRS	55 Neutral	$205.83M	―	-101.41%	―	-47.56%	-65.54%
BNR	52 Neutral	$86.58M	―	-22.66%	―	5.33%	75.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDXH	48 Neutral	$204.92M	―	―	―	22.56%	41.62%
STIM	43 Neutral	$180.52M	―	-207.57%	―	54.17%	-2.43%

Prenetics Group Corporate Events

Prenetics Reports Strong Q2 2025 Growth and Strategic Initiatives

Prenetics Global Limited announced its unaudited financial results for the second quarter of 2025, highlighting significant growth and strategic initiatives. The company’s revenue increased by 594.9% compared to the previous year, driven by the success of its IM8 Health brand, which achieved a compound annual growth rate of over 3,100% since its launch in December 2024. Prenetics aims to reach $100 million in annual recurring revenue by the end of the year and plans to achieve break-even in early 2026. The company also updated its Bitcoin treasury, accumulating 228 Bitcoins as part of its financial strategy. These developments underscore Prenetics’ strong market positioning and commitment to delivering long-term value to its stakeholders.

Prenetics Global Divests ACT Genomics Stake and Invests in Bitcoin

Prenetics Global Limited has announced the divestiture of its 70% interest in ACT Genomics Holdings Company Limited for approximately $46.3 million, marking a significant shift in its operational focus. Additionally, the company has invested $20 million in Bitcoin, acquiring 187.42 Bitcoin at an average price of $106,712 per Bitcoin, reflecting a strategic move to diversify its asset portfolio.

Prenetics Approves Major Share Capital Increase at August 2025 Meeting

On August 1, 2025, Prenetics Global Limited held an Extraordinary General Meeting of Shareholders, where they approved an increase in the company’s authorized share capital from US$50,000 to US$320,000. This decision, supported by a significant majority of shareholders, is expected to provide the company with greater flexibility for future capital raising activities, particularly in support of its Bitcoin treasury strategy and general corporate purposes. The move is anticipated to enhance Prenetics’ strategic opportunities and long-term shareholder value.